Valeant Pharmaceuticals and Salix Pharmaceuticals have amended their merger agreement from February 20, 2015. Valeant has increased the offer price  to a total value of approximately $15.8 billion, an additional $1 billion in cash or an increase of 9.5%. The amendment was approved by the boards of directors of both companies. Valeant expects to close the transaction on April 1, 2015.     “We continue to be very excited about the combination of our two companies and we are committed to gett...